Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05745064 · ClinicalTrials.gov registry record · Phase 2
A Study of TL-925 as a Treatment for Dry Eye Disease
A Phase 2 study of Dry Eye Disease, sponsored by Telios Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 4
- Study locations
NCT05745064 is a Phase 2 study of Dry Eye Disease that has completed, run by Telios Pharma. The registered enrollment target is 107 participants, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (58% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05745064, a Phase 2 study of Dry Eye Disease, has completed, sponsored by Telios Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 4
- Study locations
Study Summary
In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TL-925
Study Locations (4)
California
- Aesthetic Eye Care - Newport Beach
Colorado
- Vision Institute - Colorado Springs
Indiana
- Michael Washburn Center for Ophthalmic Research, LLC. - Indianapolis
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2023-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05745064
The ClinicalTrials.gov registry entry for NCT05745064 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (58% lower). The listed sponsor is Telios Pharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05745064 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Indiana.
Frequently Asked Questions
What is clinical trial NCT05745064 about?
NCT05745064 is a clinical study titled "A Study of TL-925 as a Treatment for Dry Eye Disease". In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bila...
What is the current status of trial NCT05745064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2023-02-27. Estimated completion is 2023-07-11.
What conditions does trial NCT05745064 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT05745064?
The interventions under investigation include: Placebo (DRUG), TL-925 (DRUG).
Who is sponsoring clinical trial NCT05745064?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05745064 being conducted?
This trial has 4 study locations across California, Colorado, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.